Your browser doesn't support javascript.
Clinical effects of intranasal corticosteroids on nasal symptoms in subjects with chronic rhinitis during COVID-19.
Tuzer, Can; Karadag, Pelin; Yegit, Ozan; Eyice, Deniz; Oztop, Nida; Can, Ali; Demir, Semra; Coskun, Raif; Erdogdu Unal, Derya; Olgac, Muge; Buyukozturk, Suna; Colakoglu, Bahattin; Gelincik, Asli.
  • Tuzer C; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Karadag P; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Yegit O; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Eyice D; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Oztop N; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Can A; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Demir S; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Coskun R; Adult Immunology and Allergy Clinic, Okmeydani Education and Research Hospital, Istanbul, Turkey.
  • Erdogdu Unal D; Adult Immunology and Allergy Clinic, Yedikule Chest Diseases and Thoracic Surgery Education and Research Hospital, Istanbul, Turkey; and.
  • Olgac M; Adult Immunology and Allergy Clinic, Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.
  • Buyukozturk S; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Colakoglu B; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
  • Gelincik A; From the Division of Immunology and Allergic Diseases, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Allergy Asthma Proc ; 43(2): 106-115, 2022 03 01.
Article in English | MEDLINE | ID: covidwho-1760175
ABSTRACT

Background:

The clinical effects of intranasal corticosteroids (INC) on nasal symptoms and the clinical course of coronavirus disease 2019 (COVID-19) in subjects with chronic rhinitis (CR) seem unclear.

Objective:

To evaluate the clinical effects of INCs on nasal symptoms in subjects with CR and with COVID-19.

Methods:

In subjects with CR and diagnosed with COVID-19 at four tertiary centers, quality of life and nasal symptoms were assessed by using the 22-item Sino-Nasal Outcome Test (SNOT-22) and the visual analog scale (VAS), respectively. In subjects with allergic rhinitis, nasal symptoms were also assessed on the total symptom score-6 (TSS-6) scale. The subjects were then allocated into two groups according to whether or not they used INCs while infected with the severe acute respiratory syndrome coronavirus 2 (group 1 and group 2, respectively). The subjects in group 2 were divided into two subgroups according to the use of antihistamines and/or leukotriene receptor antagonist or not (group 2a and group 2b, respectively). All the scores were compared before and during COVID-19 among the three groups.

Results:

A total of 71 subjects (21 in group 1, 24 in group 2a, and 26 in group 2b) were enrolled. The total scores of the SNOT-22 increased remarkably in all the groups during the infection when compared with the pre-COVID-19 scores (p < 0.001 in each group). However, the difference between the pre-COVID-19 and COVID-19 values revealed a lower decrease in the senses of smell and/or taste in group 1 than in group 2a and group 2b (p = 0.015, adjusted p = 0.045; and p = 0.001, adjusted p = 0.002, respectively). There were no significant differences in other COVID-19 findings, VAS, and TSS-6 scores among the groups (all p > 0.05).

Conclusion:

INCs in subjects with CR seemed protective against the decrease in smell and/or taste observed during COVID-19 and do not aggravate the clinical course of COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Rhinitis / COVID-19 Type of study: Diagnostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Allergy Asthma Proc Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: Aap.2022.43.210116

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Rhinitis / COVID-19 Type of study: Diagnostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Allergy Asthma Proc Journal subject: Allergy and Immunology Year: 2022 Document Type: Article Affiliation country: Aap.2022.43.210116